<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920411</url>
  </required_header>
  <id_info>
    <org_study_id>KAOS-02-16</org_study_id>
    <nct_id>NCT02920411</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis</brief_title>
  <acronym>KAOS</acronym>
  <official_title>Estudio Piloto Sobre la Efectividad de la acción Conjunta de Una Crema Corporal y un bálsamo Corporal en niños Con Dermatitis atópica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clever Instruments S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of a combined dermatological
      treatment in children up to 5 years old with mild or moderated atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intensive cream and body lotion of the PediATOPIC® products are two emollients expressly
      formulated to serve as adjuvants in the management of Atopic Dermatitis. Both products
      contain Dermosense complex®, a complex that includes 3 products: Bodyfensine peptide®
      (inductor of dephensine synthesis against microbial aggressions), Unimoist® (the mimetizing
      complex of the skin's natural hydration factor), and Ramnosoft® (polysaccharide that inhibits
      the adhesion of pro-inflammatory drugs and bacteria, while limiting the spread of
      inflammatory reactions in skin cells). They also contain Bisabolol, (plant extract with
      anti-inflammatory, anti-irritant and antimicrobial properties) and Panthenol (Pro vitamin B5
      that accelerates the skin's natural regeneration process).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Atopic Dermatitis severity according SCORAD test</measure>
    <time_frame>At 15 days</time_frame>
    <description>&lt;16 mild; &gt;16&lt;40 moderate; &gt;40 severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of atopic dermatitis outbreaks</measure>
    <time_frame>At 5 months</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable periods (between outbreaks)</measure>
    <time_frame>At 5 months</time_frame>
    <description>Register of days without outbreaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction assessed by Visual Analog Scales</measure>
    <time_frame>At 5 months</time_frame>
    <description>Validated scale for patients &lt;5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance assessed by Morisky-Green test</measure>
    <time_frame>At 5 months</time_frame>
    <description>Adherence / Compliance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Combined dermatological treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combined treatment of two emollient products will be applied:
Pediatopic treatment cream during acute stages of atopic dermatitis and
Pediatopic body lotion during stable stages</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pediatopic Treatment Cream</intervention_name>
    <description>Applied twice a day minimum.</description>
    <arm_group_label>Combined dermatological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pediatopic Body lotion</intervention_name>
    <description>Applied at libitum.</description>
    <arm_group_label>Combined dermatological treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children from 1 month to 5 years old

          -  Patients with atopic dermatitis mild-moderate with an SCORAD=16-40

        Exclusion Criteria:

          -  Other dermatological diseases that could interfere with the study results

          -  Corticoids use during 3 weeks prior to the study

          -  Antibiotics use to treat atopic dermatitis during 3 weeks prior to the study

          -  Use of topical immunomodulators

          -  Concurrent use of other emollients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sapena Jordi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Médico Quirón Teknon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M.Carmen Gavilan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Digest Pediatric Badalona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Medic Digest</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08912</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro médico Quirón Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

